In this post, we discuss the design of the Phase 1 study, what clinical data we will collect, and what it means for the value of the company and your investment.
We are excited to announce the imminent commencement of our Phase 1 clinical trial for our innovative osteoarthritis therapy, CYT-108. We recently received ethics approval from the Australian regulators – a testament to the diligence we put into the design of our Phase 1 trial and the robust preclinical data that supported the regulatory application. This milestone marks a significant advancement in our commitment to developing therapies that not only alleviate symptoms but also potentially modify the underlying disease in osteoarthritis patients.
🔍 What We Will Do
Our upcoming trial will enroll 20 participants across three distinguished clinical sites. The study is structured to include two distinct groups:
- Treatment Group: 10 patients will receive two doses of CYT-108, administered three months apart.
- Control Group: 10 patients will receive a saline placebo following the same schedule.
Post-administration, all participants will undergo a rigorous three-month follow-up period. We expect to have the first patient dosed in the next few weeks, and the last patient dosed before December 2024. Our goal is to have the final Phase 1 study report published in early 2H25.
👀 What We Will Look For
The primary goal of this phase is to evaluate the safety and tolerability of CYT-108. However, the scope of our study extends beyond just safety:
- Efficacy Assessment: The effectiveness of CYT-108 will be measured using the WOMAC (Western Ontario and McMaster Universities Arthritis Index) score, which assesses pain, stiffness, and physical function in osteoarthritis patients.
- Disease Modification: A crucial component of our trial involves the ARGS assay, a biomarker assay that detects fragments specifically cleaved from aggrecan (a key cartilage component) by the aggrecanases, enzymes active in osteoarthritis. This assay will help us identify potential disease-modifying effects of CYT-108, an aspect seldom addressed by current therapies.
🎉 Optimizing Success
The development of CYT-108 is significantly de-risked by our prior experiences with our APIC therapy (our flagship therapy for OA that has treated over 8,000 patients to date) and robust preclinical research. Drawing on APIC’s use of naturally occurring A2M, we’ve established an effective starting dose of approximately 25mg for CYT-108, ensuring a safe and informed entry into human trials. Additionally, we know that the A2M protein can be delivered in high concentrations into the joints of animals without any adverse effects, further de-risking the safety of the study. This foundational work enhances our confidence in advancing a therapy that is both safe and potentially transformative for osteoarthritis patients.
CYT-108, a synthetic variant of the A2M protein, is de-risked in a way that most de novo therapies are not because we know that the core A2M protein is an effective therapy for OA.
🌐 Looking Forward
As we move forward with these trials, our goal is not just to establish the safety and preliminary efficacy of CYT-108 but to pave the way for a treatment that could fundamentally change the management of osteoarthritis. We believe that CYT-108 has the potential to be a groundbreaking therapy that offers hope to millions suffering from this debilitating disease.
We invite our investors and the broader community to stay tuned for updates as we progress through this pivotal phase of our research. Your support is crucial in our journey to redefine osteoarthritis treatment.
Ready to become a shareholder? Visit invest.cytonics.com.
This communication may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.
Leave a Reply